Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company`s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Website: 908devices.com



Growth: Good revenue growth rate 11.1%, there is slowdown compared to average historical growth rates 22.8%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -98.0%. On average the margin is improving steadily. Gross margin is high, +50.1%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -7.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 14.0% higher than minimum and 88.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -2.3x by EV / Sales multiple

Key Financials (Download financials)

Ticker: MASS
Share price, USD:  (-0.4%)5.65
year average price 7.16  


year start price 7.09 2023-05-07

min close price 4.96 2023-11-09

max close price 12.41 2023-12-28

current price 5.65 2024-05-05
Common stocks: 32 710 894

Dividend Yield:  0.0%
Last revenue growth (y/y):  11.1%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  22.8%
Historical growth of EBITDA:  0.0%
EV / Sales: 1.1x
Margin (EBITDA LTM / Revenue): -98.0%
Fundamental value created in LTM:
Market Cap ($m): 185
Net Debt ($m): -132
EV (Enterprise Value): 53
Price to Book: 1.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-30Seeking Alpha

908 Devices Inc. (MASS) Q1 2024 Earnings Call Transcript

2024-04-30Zacks Investment Research

908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates

2023-12-28Zacks Investment Research

908 Devices Inc. (MASS) Upgraded to Buy: What Does It Mean for the Stock?

2023-08-31Seeking Alpha

908 Devices: Not Worth Investing

2023-08-08Seeking Alpha

908 Devices, Inc. (MASS) Q2 2023 Earnings Call Transcript

2023-08-08Zacks Investment Research

908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates

2023-07-13Zacks Investment Research

908 Devices Inc. (MASS) Soars 8.5%: Is Further Upside Left in the Stock?

2023-05-09Zacks Investment Research

908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MASS MASS MASS MASS MASS MASS MASS
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-03 2024-03-08 2023-11-07 2023-08-08 2023-05-09 2023-03-15 2022-11-14
acceptedDate 2024-05-03 08:45:43 2024-03-08 16:15:45 2023-11-07 08:46:06 2023-08-08 09:15:47 2023-05-09 08:45:41 2023-03-15 16:31:02 2022-11-14 09:16:07
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 10M 14M 14M 12M 9M 12M 16M
costOfRevenue 6M 7M 6M 6M 5M 6M 6M
grossProfit 4M 7M 8M 6M 4M 6M 9M
grossProfitRatio 0.390 0.486 0.550 0.479 0.462 0.509 0.591
researchAndDevelopmentExpenses 5M 5M 6M 6M 5M 5M 5M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 12M 11M 11M 11M 12M 12M 12M
otherExpenses 0 -43 000 110 000 2M 485 000 547 000 0
operatingExpenses 17M 17M 17M 17M 17M 16M 16M
costAndExpenses 23M 24M 23M 23M 23M 22M 23M
interestIncome 2M 2M 2M 2M 1M 0 0
interestExpense 0 -1M 350 000 0 551 000 61 000 33 000
depreciationAndAmortization 1M 405 000 740 000 605 000 634 000 577 000 1M
ebitda -11M -9M -8M -11M -13M -10M -6M
ebitdaratio -1.137 -0.647 -0.584 -0.904 -1.372 -0.888 -0.365
operatingIncome -13M -10M -9M -11M -13M -10M -7M
operatingIncomeRatio -1.270 -0.675 -0.636 -0.904 -1.372 -0.888 -0.453
totalOtherIncomeExpensesNet 2M 2M 110 000 2M 485 000 547 000 895 000
incomeBeforeTax -11M -7M -7M -9M -13M -10M -6M
incomeBeforeTaxRatio -1.100 -0.518 -0.502 -0.779 -1.321 -0.841 -0.396
incomeTaxExpense -70 000 -2000.000 -87 000 -71 000 -2M -547 000 -895 000
netIncome -11M -7M -7M -9M -11M -9M -5M
netIncomeRatio -1.093 -0.518 -0.496 -0.773 -1.145 -0.794 -0.340
eps -0.330 -0.230 -0.220 -0.290 -0.340 -0.290 -0.170
epsdiluted -0.330 -0.230 -0.220 -0.290 -0.340 -0.290 -0.170
weightedAverageShsOut 33M 32M 32M 32M 32M 32M 32M
weightedAverageShsOutDil 33M 32M 32M 32M 32M 32M 32M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MASS MASS MASS MASS MASS MASS MASS
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-03 2024-03-08 2023-11-07 2023-08-08 2023-05-09 2023-03-15 2022-11-14
acceptedDate 2024-05-03 08:45:43 2024-03-08 16:15:45 2023-11-07 08:46:06 2023-08-08 09:15:47 2023-05-09 08:45:41 2023-03-15 16:31:02 2022-11-14 09:16:07
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 105M 121M 118M 133M 161M 188M 194M
shortTermInvestments 30M 25M 30M 20M 0 0 0
cashAndShortTermInvestments 134M 146M 148M 153M 161M 188M 194M
netReceivables 7M 9M 13M 10M 8M 10M 15M
inventory 16M 15M 16M 14M 13M 13M 12M
otherCurrentAssets 4M 4M 3M 4M 5M 5M 3M
totalCurrentAssets 162M 174M 180M 181M 188M 216M 224M
propertyPlantEquipmentNet 9M 10M 10M 10M 11M 7M 7M
goodwill 10M 10M 10M 10M 10M 10M 9M
intangibleAssets 7M 8M 8M 8M 8M 8M 8M
goodwillAndIntangibleAssets 18M 18M 18M 18M 19M 19M 17M
longTermInvestments -2M 171 000 -2M -3M 0 0 0
taxAssets 2M 8M 2M 3M 3M 0 0
otherNonCurrentAssets 1M -7M 1M 1M -1M 1M 1M
totalNonCurrentAssets 28M 29M 29M 30M 30M 27M 25M
otherAssets 0 0 0 0 0 0 0
totalAssets 190M 203M 208M 211M 218M 243M 249M
accountPayables 1M 1M 3M 1M 2M 1M 2M
shortTermDebt 2M 2M 2M 2M 2M 1M 1M
taxPayables 0 0 0 0 0 0 0
deferredRevenue 10M 11M 11M 11M 8M 8M 7M
otherCurrentLiabilities 5M 9M 7M 6M 7M 9M 9M
totalCurrentLiabilities 19M 23M 22M 20M 19M 19M 19M
longTermDebt 3M 4M 4M 5M 5M 15M 18M
deferredRevenueNonCurrent 8M 9M 9M 8M 11M 11M 12M
deferredTaxLiabilitiesNonCurrent 2M 2M 2M 3M 3M 3M 3M
otherNonCurrentLiabilities 0 0 0 156 000 125 000 4M 23M
totalNonCurrentLiabilities 14M 15M 16M 16M 19M 33M 34M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 3M 4M 6M 2M 2M 1M 5M
totalLiabilities 33M 37M 39M 36M 38M 52M 53M
preferredStock 0 0 0 0 0 0 0
commonStock 33 000 33 000 32 000 32 000 32 000 32 000 32 000
retainedEarnings -182M -171M -163M -156M -147M -134M -124M
accumulatedOtherComprehensiveIncomeLoss 980 000 1M 988 000 1M 1M 798 000 -613 000
othertotalStockholdersEquity 337M 335M 332M 329M 326M 324M 321M
totalStockholdersEquity 157M 165M 170M 174M 181M 191M 197M
totalEquity 157M 165M 170M 174M 181M 191M 197M
totalLiabilitiesAndStockholdersEquity 190M 203M 208M 211M 218M 243M 249M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 190M 203M 208M 211M 218M 243M 249M
totalInvestments 30M 25M 30M 20M 0 0 0
totalDebt 5M 6M 6M 2M 2M 16M 20M
netDebt -99M -115M -112M -131M -160M -172M -174M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MASS MASS MASS MASS MASS MASS MASS
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-03 2024-03-08 2023-11-07 2023-08-08 2023-05-09 2023-03-15 2022-11-14
acceptedDate 2024-05-03 08:45:43 2024-03-08 16:15:45 2023-11-07 08:46:06 2023-08-08 09:15:47 2023-05-09 08:45:41 2023-03-15 16:31:02 2022-11-14 09:16:07
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -11M -7M -7M -9M -13M -10M -6M
depreciationAndAmortization 1M 405 000 740 000 605 000 634 000 577 000 459 000
deferredIncomeTax -70 000 -66 000 -117 000 -72 000 -50 000 -129 000 0
stockBasedCompensation 0 2M 3M 3M 2M 2M 2M
changeInWorkingCapital -2M 3M -853 000 -2M -2M 2M -1M
accountsReceivables 1M 4M -3M -2M 2M 5M -4M
inventory -2M -61 000 -2M -690 000 -990 000 -1M -251 000
accountsPayables -2M 805 000 3M 681 000 -339 000 1M 0
otherWorkingCapital -467 000 -2M 606 000 401 000 -2M -3M 3M
otherNonCashItems 7M 130 000 17 000 211 000 689 000 528 000 11 000
netCashProvidedByOperatingActivities -9M -2M -5M -8M -11M -5M -5M
investmentsInPropertyPlantAndEquipment -903 000 -333 000 -207 000 -320 000 -1M -612 000 -744 000
acquisitionsNet 0 -5M -5M 0 0 -14M 0
purchasesOfInvestments -15M -15M -15M -20M 0 0 0
salesMaturitiesOfInvestments 10M 20M 5M 0 0 0 0
otherInvestingActivites 0 5M 5M 0 0 14M -14M
netCashUsedForInvestingActivites -6M 5M -10M -20M -1M -612 000 -15M
debtRepayment 0 -15M 0 0 -15M -15M -15M
commonStockIssued 61 000 273 000 15 000 560 000 88 000 2M 0
commonStockRepurchased 0 -178 000 -68 000 -61 000 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites -1M -178 000 -195 000 -900 000 -469 000 14M 15M
netCashUsedProvidedByFinancingActivities -1M 95 000 -248 000 -401 000 -15M 411 000 171 000
effectOfForexChangesOnCash -10000.000 27 000 -20 000 1000.000 5000.000 41 000 0
netChangeInCash -16M 3M -15M -28M -27M -5M -19M
cashAtEndOfPeriod 105M 121M 118M 133M 161M 189M 194M
cashAtBeginningOfPeriod 121M 118M 133M 161M 189M 194M 213M
operatingCashFlow -9M -2M -5M -8M -11M -5M -5M
capitalExpenditure -903 000 -333 000 -207 000 -320 000 -1M -612 000 -744 000
freeCashFlow -10M -2M -5M -8M -12M -6M -6M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-04-30 ET (fiscal 2024 q1)
2023 q4
2024-03-05 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q1
2023-05-12 ET (fiscal 2023 q1)
2022 q4
2023-03-07 ET (fiscal 2022 q4)
2022 q3
2022-11-14 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-10 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-30 11:45 ET
908 Devices Reports First Quarter 2024 Financial Results and Updates 2024 Revenue Outlook
2024-04-30 11:30 ET
908 Devices Acquires RedWave Technology, Expanding its Forensics Product Offering
2024-04-23 11:00 ET
908 Devices to Report First Quarter 2024 Financial Results on April 30, 2024
2024-03-12 11:00 ET
908 Devices Trace Chemical Identification Technology Adopted by European Agencies
2024-03-05 12:00 ET
908 Devices Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Revenue Outlook
2024-02-29 12:00 ET
908 Devices and Cellares Collaborate to Integrate In-line Monitoring of Bioprocess Parameters into the Cell Shuttle, Cellares’ Fully Integrated Cell Therapy Manufacturing Platform
2024-02-22 12:00 ET
908 Devices to Participate in Upcoming Investor Conferences
2024-02-20 12:00 ET
908 Devices to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
2023-11-14 12:00 ET
908 Devices Announces MX908 Integration Capabilities
2023-11-07 12:00 ET
908 Devices Reports Third Quarter 2023 Financial Results and Narrows 2023 Revenue Outlook
2023-11-06 21:30 ET
908 Devices and Terumo Blood and Cell Technologies Collaborate to Add On-line Analytics to Quantum Flex Cell Expansion System
2023-10-31 11:00 ET
908 Devices to Participate in Upcoming Investor Conferences
2023-10-24 20:30 ET
908 Devices Awarded $10.4M Order from the United States Air Force for its Handheld MX908 Device
2023-10-24 11:00 ET
908 Devices to Report Third Quarter Financial Results on November 7, 2023
2023-09-26 11:00 ET
908 Devices Enters Initial Production Phase of US Department of Defense Aerosol and Vapor Chemical Agent Detector Program
2023-09-18 11:00 ET
908 Devices Launches MAVERICK for Real-Time In-Line Monitoring of Multiple Bioprocess Parameters
2023-09-15 11:00 ET
908 Devices to Participate in the Gilmartin Group Emerging Growth Company Showcase
2023-08-08 11:00 ET
908 Devices Reports Second Quarter 2023 Financial Results and Updates 2023 Revenue Outlook
2023-08-07 11:00 ET
908 Devices Partners with Tennessee State and Local Agencies in the Fight Against Drug Trafficking Through a New Pilot Program
2023-07-31 11:00 ET
908 Devices Launches Remote and Continuous Area Monitoring for Aerosol and Vapor Detection
2023-07-25 11:00 ET
908 Devices to Report Second Quarter Financial Results on August 8, 2023
2023-05-30 11:00 ET
908 Devices Features its High-Speed, High-Resolution Separations Technology at the 71st ASMS Conference
2023-05-23 11:00 ET
908 Devices to Participate in the William Blair 43rd Annual Growth Stock Conference
2023-05-09 11:00 ET
908 Devices Reports First Quarter 2023 Financial Results and Reiterates 2023 Revenue Outlook
2023-05-04 11:00 ET
908 Devices Launches Data Analysis Visualization Tool for REBEL At-line Cell Culture Media Analyzer
2023-04-26 11:00 ET
Resilience Demonstrates Lower Cost of Perfusion Bioreactor Process Using 908 Devices’ REBEL At-line Analyzer
2023-04-25 11:00 ET
908 Devices to Report First Quarter Financial Results on May 9, 2023
2023-03-07 12:00 ET
908 Devices Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Revenue Outlook
2023-02-21 12:00 ET
908 Devices to Participate in the Cowen 43rd Annual Healthcare Conference
2023-02-14 12:00 ET
908 Devices to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
2023-01-17 12:00 ET
908 Devices Unveils New Glucose and Lactate On-Line Device for Bioprocess Monitoring and Control
2022-12-07 12:00 ET
MX908 Device Enables Correctional Facility Personnel to Quickly Identify Illegal Drugs in Incoming Mail
2022-11-14 12:00 ET
908 Devices Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Outlook
2022-11-10 12:00 ET
908 Devices Records Strong Momentum in Life Sciences Sector
2022-11-09 12:00 ET
908 Devices Launches Pesticide Identification Capability to Thwart Illegal Marijuana Growing Operations
2022-11-02 11:00 ET
908 Devices to Participate in Upcoming Investor Conferences
2022-10-19 11:00 ET
908 Devices to Report Third Quarter 2022 Financial Results on November 14, 2022
2022-10-12 21:00 ET
908 Devices and CPI Improve mAbs Cell Culture Outcomes Using At-line Media Analysis
2022-08-09 11:30 ET
908 Devices Reports Second Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook
2022-08-09 11:00 ET
908 Devices Acquires TRACE Analytics, Enabling On-line Bioanalytics
2022-07-27 11:00 ET
908 Devices to Participate in the Canaccord Genuity 42nd Annual Growth Conference
2022-07-19 11:00 ET
908 Devices to Report Second Quarter 2022 Financial Results on August 9, 2022
2022-06-02 11:00 ET
908 Devices Showcases Technology for Accelerating Mass Spec Workflows in Presentations at ASMS
2022-05-26 11:00 ET
908 Devices to Participate in the William Blair 42nd Annual Growth Stock Conference
2022-05-10 11:00 ET
908 Devices Reports First Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook
2022-05-09 11:00 ET
908 Devices Advances MX908 Handheld Device Capabilities
2022-05-03 11:00 ET
908 Devices Partners with Key Biomanufacturing Innovation Center
2022-04-21 11:00 ET
908 Devices and CPI Team on Cell Culture Media Optimization for Improved Process Control in Bioprocessing Applications
2022-04-12 11:00 ET
908 Devices to Report First Quarter Financial Results on May 10, 2022
2022-03-07 21:05 ET
908 Devices Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Revenue Outlook
2022-03-02 21:30 ET
908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors
2022-02-15 12:00 ET
908 Devices to Report Fourth Quarter and Full Year 2021 Financial Results on March 7, 2022
2022-02-08 12:00 ET
908 Devices to Participate in Upcoming Investor Conferences
2022-01-10 00:00 ET
908 Devices Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
2022-01-07 12:00 ET
908 Devices Announces GSK Purchases Fifth REBEL Cell Culture Media Analyzer
2022-01-04 22:00 ET
908 Devices and U.S. Forest Service Announce Development Collaboration
2021-12-22 12:00 ET
908 Devices Teams With World-Renowned Guardian Centers of Georgia for First Responder Training
2021-11-11 12:00 ET
908 Devices to Participate in Upcoming Investor Conferences
2021-11-11 00:40 ET
908 Devices Announces Pricing of Public Offering
2021-11-08 21:15 ET
908 Devices Announces Launch of Public Offering
2021-11-04 11:00 ET
908 Devices Reports Third Quarter 2021 Financial Results
2021-11-01 11:00 ET
908 Devices Launches Oligos Kit for its ZipChip CE-MS Device
2021-10-27 11:00 ET
908 Devices to Exhibit at ASMS and Present Key Developments in Accelerating Proteomics Workflows
2021-10-21 11:00 ET
908 Devices to Report Third Quarter Financial Results on November 4, 2021
2021-08-04 11:00 ET
908 Devices Reports Second Quarter 2021 Financial Results and Raises 2021 Revenue Outlook
2021-08-02 11:00 ET
908 Devices Expands Scientific Advisory Board, Creates Dedicated Proteomics Panel
2021-07-28 11:00 ET
908 Devices Expands Strategic Distribution Network in APAC, Europe, and the Americas
2021-07-22 11:00 ET
908 Devices and Transcenta’s Joint Innovation Partnership Accelerates Biopharma Development
2021-07-21 12:00 ET
908 Devices to Report Second Quarter Financial Results on August 4, 2021
2021-06-08 11:00 ET
908 Devices Appoints Marcia Eisenberg, Ph.D., Chief Scientific Officer of Labcorp Diagnostics, to its Board of Directors
2021-05-20 12:00 ET
908 Devices to Participate in the William Blair 41st Annual Growth Stock Conference
2021-05-13 11:00 ET
908 Devices Reports First Quarter 2021 Financial Results and Reiterates 2021 Revenue Outlook
2021-05-11 11:00 ET
908 Devices Launches New Aerosol Module for Handheld MX908
2021-05-07 11:00 ET
908 Devices Increases Focus on Biotherapeutics with Expansion of Scientific Advisory Board
2021-05-04 11:00 ET
908 Devices and Bio-Techne Announce Joint Collaboration
2021-05-04 11:00 ET
Bio-Techne and 908 Devices Announce Joint Collaboration
2021-04-14 12:00 ET
908 Devices to Report First Quarter Financial Results on May 13, 2021 and Host 2021 Annual Meeting of Stockholders on June 17, 2021
2021-04-13 11:00 ET
908 Devices Appoints Michele Fournier as Chief People Officer
2021-04-08 11:00 ET
908 Devices Provides Handheld Mass Spec for Trace Detection to U.S. Border Patrol
2021-03-30 11:00 ET
908 Devices Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Revenue Outlook
2021-03-30 10:55 ET
908 Devices Awarded Multi-Year $25M Purchase Order to Enable the U.S. Army
2021-02-23 13:00 ET
908 Devices Appoints Jeff George and Fenel Eloi to its Board of Directors
2021-02-22 13:00 ET
908 Devices to Report Fourth Quarter and Full Year 2020 Financial Results on March 30, 2021
2021-02-16 13:00 ET
908 Devices to Participate in Upcoming Investor Conferences
2021-02-09 14:00 ET
908 Devices Strengthens Commercial Team with Addition of New Vice President
2020-12-22 22:23 ET
908 Devices Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
2020-12-18 03:38 ET
908 Devices Announces Pricing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2024-05-03 00:00 ET
908 Devices Inc. published news for 2024 q1
SEC form 8
2024-04-30 08:05 ET
908 Devices Inc. published news for 2024 q1
SEC form 8
2024-04-30 08:05 ET
908 Devices Inc. reported for 2024 q1
SEC form 10
2024-03-08 16:15 ET
908 Devices Inc. published news for 2023 q4
SEC form 10
2024-03-08 00:00 ET
908 Devices Inc. published news for 2023 q4
SEC form 8
2024-03-05 07:15 ET
908 Devices Inc. published news for 2023 q4
SEC form 8
2024-03-05 07:15 ET
908 Devices Inc. reported for 2023 q4
SEC form 10
2023-11-07 08:46 ET
908 Devices Inc. published news for 2023 q3
SEC form 8
2023-11-07 07:15 ET
908 Devices Inc. reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
908 Devices Inc. published news for 2023 q3
SEC form 10
2023-08-08 09:15 ET
908 Devices Inc. reported for 2023 q2
SEC form 6
2023-08-08 07:15 ET
908 Devices Inc. published news for 2023 q2
SEC form 10
2023-08-08 00:00 ET
908 Devices Inc. published news for 2023 q2
SEC form 6
2023-06-16 16:05 ET
908 Devices Inc. published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
908 Devices Inc. published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
908 Devices Inc. published news for 2023 q1
SEC form 6
2023-05-01 09:51 ET
908 Devices Inc. published news for 2023 q1
SEC form 10
2023-03-15 16:31 ET
908 Devices Inc. reported for 2022 q4
SEC form 10
2023-03-15 00:00 ET
908 Devices Inc. reported for 2022 q4
SEC form 6
2023-03-07 07:15 ET
908 Devices Inc. published news for 2022 q4
SEC form 8
2023-03-07 00:00 ET
908 Devices Inc. reported for 2022 q4
SEC form 10
2022-11-14 09:16 ET
908 Devices Inc. reported for 2022 q3
SEC form 6
2022-11-14 07:15 ET
908 Devices Inc. published news for 2022 q3
SEC form 8
2022-11-14 00:00 ET
908 Devices Inc. reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
908 Devices Inc. reported for 2022 q3
SEC form 6
2022-11-08 09:15 ET
908 Devices Inc. published news for 2022 q3
SEC form 6
2022-08-09 07:45 ET
908 Devices Inc. published news for 2022 q2
SEC form 10
2022-08-09 07:26 ET
908 Devices Inc. reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
908 Devices Inc. reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
908 Devices Inc. reported for 2022 q2
SEC form 6
2022-06-17 16:10 ET
908 Devices Inc. published news for 2022 q1
SEC form 10
2022-05-10 08:30 ET
908 Devices Inc. reported for 2022 q1
SEC form 6
2022-05-10 07:15 ET
908 Devices Inc. published news for 2022 q1
SEC form 8
2022-05-10 00:00 ET
908 Devices Inc. reported for 2022 q1
SEC form 10
2022-05-10 00:00 ET
908 Devices Inc. reported for 2022 q1
SEC form 6
2022-04-21 07:00 ET
908 Devices Inc. published news for 2022 q1
SEC form 6
2022-04-11 16:01 ET
908 Devices Inc. published news for 2022 q1
SEC form 10
2022-03-11 08:30 ET
908 Devices Inc. published news for 2021 q4
SEC form 10
2022-03-11 00:00 ET
908 Devices Inc. published news for 2021 q4
SEC form 6
2022-03-07 16:05 ET
908 Devices Inc. published news for 2021 q4
SEC form 8
2022-03-07 00:00 ET
908 Devices Inc. published news for 2021 q4
SEC form 6
2022-03-02 16:45 ET
908 Devices Inc. published news for 2021 q4
SEC form 6
2022-01-10 07:30 ET
908 Devices Inc. published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
908 Devices Inc. published news for 2021 q4
SEC form 10
2021-11-04 09:15 ET
908 Devices Inc. published news for 2021 q3
SEC form 6
2021-11-04 07:16 ET
908 Devices Inc. published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
908 Devices Inc. published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
908 Devices Inc. published news for 2021 q3
SEC form 10
2021-08-04 09:16 ET
908 Devices Inc. published news for 2021 q2
SEC form 6
2021-08-04 07:15 ET
908 Devices Inc. published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
908 Devices Inc. published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
908 Devices Inc. published news for 2021 q2
SEC form 6
2021-06-23 16:05 ET
908 Devices Inc. published news for 2021 q1
SEC form 6
2021-06-09 19:18 ET
908 Devices Inc. published news for 2021 q1
SEC form 6
2021-06-08 07:31 ET
908 Devices Inc. published news for 2021 q1
SEC form 10
2021-05-13 09:16 ET
908 Devices Inc. published news for 2021 q1
SEC form 6
2021-05-13 07:16 ET
908 Devices Inc. published news for 2021 q1
SEC form 8
2021-05-13 00:00 ET
908 Devices Inc. published news for 2021 q1
SEC form 10
2021-05-13 00:00 ET
908 Devices Inc. published news for 2021 q1
SEC form 6
2021-04-29 07:00 ET
908 Devices Inc. published news for 2021 q1
SEC form 10
2021-03-31 09:00 ET
908 Devices Inc. published news for 2020 q4
SEC form 6
2021-03-30 07:15 ET
908 Devices Inc. published news for 2020 q4
SEC form 6
2021-03-15 16:20 ET
908 Devices Inc. published news for 2020 q4
SEC form 6
2021-03-02 19:02 ET
908 Devices Inc. published news for 2020 q4
SEC form 6
2021-03-02 19:00 ET
908 Devices Inc. published news for 2020 q4
SEC form 6
2021-02-23 16:33 ET
908 Devices Inc. published news for 2020 q4
SEC form 6
2020-12-17 20:08 ET
908 Devices Inc. published news for 2020 q3
SEC form 6
2020-12-17 20:08 ET
908 Devices Inc. published news for 2020 q3
SEC form 6
2020-12-17 20:08 ET
908 Devices Inc. published news for 2020 q3
SEC form 6
2020-12-17 20:07 ET
908 Devices Inc. published news for 2020 q3
SEC form 6
2020-12-17 20:07 ET
908 Devices Inc. published news for 2020 q3
SEC form 6
2020-12-17 20:06 ET
908 Devices Inc. published news for 2020 q3
SEC form 6
2020-12-17 20:06 ET
908 Devices Inc. published news for 2020 q3
SEC form 6
2020-12-17 20:06 ET
908 Devices Inc. published news for 2020 q3
SEC form 6
2020-12-17 20:05 ET
908 Devices Inc. published news for 2020 q3
SEC form 6
2020-12-17 20:04 ET
908 Devices Inc. published news for 2020 q3
SEC form 6
2020-12-17 20:03 ET
908 Devices Inc. published news for 2020 q3
SEC form 6
2020-12-17 20:03 ET
908 Devices Inc. published news for 2020 q3